Global Lower Respiratory Tract Disease Diagnosis and Treatment Market 2023-2030

Global Lower Respiratory Tract Disease Diagnosis and Treatment Market 2023-2030

Global Lower Respiratory Tract Disease Diagnosis and Treatment Market Size, Share & Trends Analysis Report by Condition (Pneumonia, Bronchitis, Tuberculosis, and Others), by Diagnosis (Mucus Samples, Blood Tests, Chest X-Rays, and Pulse Oximetry), and by Treatment (Non-Steroidal Anti-Inflammatory Drugs (NSAIDs), Analgesics and, Antipyretic Drugs, Bronchodilator Inhaler and Others), and by Category (Over-the-Counter (OTC) and Prescription), Forecast Period (2023-2030)

The global lower respiratory tract disease diagnosis and treatment market is anticipated to grow at a CAGR of 7.4% during the forecast period (2023-2030). The lower respiratory tract disease diagnosis and treatment market is driven by the rising incidence of lower respiratory tract diseases, the aging population, increased awareness and diagnosis, government initiatives and healthcare policies, environmental variables (such as air pollution, climate change, and allergens), and innovations in technology. Owing to the day-by-day degrading air quality of several nations around the globe has propelled the incidence of cold, cough, and allergies. Hence, there were several initiatives witnessed aiming to improve the air quality index (AQI) while providing well-efficient healthcare facilities for the treatment of such infections. For instance, in March 2023, the ultra-low emission zones (ULEZ) project in London employed mobile air quality monitoring technology to track air quality and intends to cut one million hospital admissions by 2050. It tries to prevent lower respiratory tract problems brought on by polluted air.

Segmental Outlook

The global lower respiratory tract disease diagnosis and treatment market is segmented by condition, diagnosis, treatment, and category. Based on the conditions, the market is sub-segmented into pneumonia, bronchitis, tuberculosis, and others (influenza). Based on the diagnosis, the market is sub-segmented into mucus samples, blood tests, chest X-rays, and pulse oximetry. Based on the treatment, the market is sub-segmented into NSAIDs, analgesics and antipyretics, bronchodilator inhalers, and others (antibiotics). Further, on the basis of category, the market is bifurcated into OTC and prescription. Among the conditions, the bronchitis sub-segment is anticipated to hold a considerable share of the market owing to the rise in prevalence of bronchitis cases coupled with the rise in development of new and more effective medications treating bronchitis.

The Bronchodilator Inhaler Sub-Segment is Anticipated to Hold a Considerable Share of the Market

Among the treatments, the bronchodilator inhaler sub-segment is expected to hold a considerable share of the global lower respiratory tract disease diagnosis and treatment market. The segmental growth is attributed to the growing influence of combination therapies. Combination therapies, which combine two or more bronchodilator inhaler medications, are becoming increasingly common as they provide better therapeutic results and are more convenient for patients. For instance, in August 2020, Teva Pharmaceutical Industries Ltd. introduced ProAir® Digihaler® (albuterol sulfate 117 mcg) Inhalation Powder, the first and only digital rescue inhaler approved for use in patients aged 4 years and above. The inhaler is used to treat and prevention bronchospasm in those with reversible obstructive airway disease, as well as for the avoidance of exercise-induced bronchospasm (EIB).

Regional Outlook

The global lower respiratory tract disease diagnosis and treatment market is further segmented based on geography including North America (the US, and Canada), Europe (UK, Italy, Spain, Germany, France, and the Rest of Europe), Asia-Pacific (India, China, Japan, South Korea, and Rest of Asia), and the Rest of the World (the Middle East & Africa, and Latin America). Among these, the Asia-Pacific region is anticipated to hold a prominent share of the market across the globe, owing to the unhealthy lifestyles of the regional population. Expanding the healthcare infrastructure and increasing patient awareness are another factor to boost the regional market growth.

Global Lower Respiratory Tract Disease Diagnosis and Treatment Market Growth by Region 2023-2030

Source: OMR Analysis

North America is Expected to Grow at a Significant CAGR in the Global Lower Respiratory Tract Disease Diagnosis and Treatment Market

Among all regions, the North America is anticipated to grow at a significant CAGR over the forecast period. Growing geriatric populations, immune-compromised seniors, and multi-drug resistant bacterial infections in children are some factors contributing to the region's market growth. Lower respiratory tract diseases, such as asthma, COPD, pneumonia, and bronchitis, among others, imposes a significant burden on global healthcare systems. Hence, the growing prevalence of these diseases will propel the demand for lower respiratory tract diseases diagnosis and treatments. According to the American Lung Association (ALA), around 10 million Americans are suffering from acute bronchitis, owing to the smoking. Resultantly, the non-profit government organization (NGOs) in collaboration with private and government institutions are introducing various campaigns and programmes creating awareness among the population in the US. For instance, in May 2023, Grifols, introduced first-ever free direct-to-consumer program in the US to screen for the genetic risk of COPD. The programme was unveiled by a company that produces plasma-derived medications and innovative diagnostic technologies. The initiative is named as AlphaID At Home.

Market Players Outlook

The major companies serving the lower respiratory tract disease diagnosis and treatment market include AbbVie Inc., GlaxoSmithKline plc, Johnson & Johnson Pvt. Ltd., Merck & Co., Inc., Novartis AG, Takeda Pharmaceutical Company Ltd., and others. The market players are considerably contributing to the market growth by the adoption of various strategies including mergers and acquisitions, partnerships, collaborations, funding, and new product launches, to stay competitive in the market. For instance, in April 2022, Pfizer Inc. and ReViral Ltd. entered into a binding agreement under which Pfizer acquired ReViral for worth $525 million. Through this acquisition, Pfizer aims to strengthen its infectious diseases R&D capabilities and enhance its treatment of RSVs.

The Report Covers

Market value data analysis of 2022 and forecast to 2030.

Annualized market revenues ($ million) for each market segment.

Country-wise analysis of major geographical regions.

Key companies operating in the global lower respiratory tract disease diagnosis and treatment market. Based on the availability of data, information related to new product launches, and relevant news is also available in the report.

Analysis of business strategies by identifying the key market segments positioned for strong growth in the future.

Analysis of market-entry and market expansion strategies.

Competitive strategies by identifying ‘who-stands-where’ in the market.